Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -4.00 -0.48% 836.00 820.00 850.00 845.00 835.00 845.00 434,142 16:35:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 621

Maxcyte Share Discussion Threads

Showing 301 to 325 of 675 messages
Chat Pages: Latest  15  14  13  12  11  10  9  8  7  6  5  4  Older
DateSubjectAuthorDiscuss
23/12/2020
08:03
Very good! TU during dead xmas days is usually bad news...very pleasing to see trading still very strong! Continue think this can 10-bag
adamb1978
23/12/2020
07:09
Wed, 23rd Dec 2020 07:00 RNS Number : 6024J MaxCyte, Inc. 23 December 2020 TRADING UPDATE MaxCyte to exceed 2020 Full Year market expectations Gaithersburg, Maryland - 23 December 2020: MaxCyte (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announces an update on trading for the full year 2020 and progress of the CARMA programme. Based on ongoing momentum in transformational cell therapies and milestone payments from growth in clinical and commercial license partnerships, MaxCyte expects financial results to be ahead of market expectations for the full-year in the core life sciences business (before CARMA costs). A more detailed trading update will be announced the week of 18 January 2021. MaxCyte continues to work with Locust Walk on the strategy and future funding of the Group's CARMA business, and enrolment and dosing in the existing CARMA no-preconditioning MCY-M11 clinical study is continuing well. The Company will provide a further update in January. MaxCyte President & CEO, Doug Doerfler, said: "We have seen sustained strong growth in our core life sciences business as demand for our next generation gene and cell therapy enabling products continues to expand internationally, despite the issues that COVID-19 has placed around the globe. MaxCyte continues to be uniquely positioned to capitalise on the rapidly growing cell therapy market."
multibagger
22/12/2020
08:30
Thats only part right in my experience. The truth is if there is excitement there are buyers and its buyers that drive the shareprice. Excitement and anticipation of the future matters a great deal alongside cashflow projections - they are both as important as each other. I wouldn't mind some Crispr / Editas style price action myself whatever my DCF calculations show. Out of interest what do your projections show?
nimbo1
22/12/2020
08:16
The excitement s/be worth Diddley squat - it's cash generation that is worth something.
trident5
21/12/2020
22:13
It deserves to go bonkers but im not sure if it will..its on aim! The crispr drug causing excitement could be worth c.60/70 million dollars per annum to maxcyte at peak sales... that’s one of 60(?, of course only a percentage make it to market)...but that 1 alone underpins the price imo. I think this should be nearer 10 pounds sometime next year on Nasdaq float.
nimbo1
21/12/2020
18:16
And Crispy also having a good day. Certainly clues emerging with this one (although misleading when it comes to open price next day) a UT trade of 16k shares and a late reported 2.5k both at full ask. Wonder if we will actually get the Carma news this year but anyway the NASDAQ listing should light the blue touchpaper. Roll on 2021 ,for a host of reasons !
assagai
21/12/2020
17:43
is this about to break out? Similar stocks (BEAM and EDITAS) going bonkers today in the USA.
davemac3
16/12/2020
15:42
For those wondering there will be a general update 'early jan'.
nimbo1
10/12/2020
13:28
hxxps://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-submission-ind-application-edit-301 This sounds like more good news for us
nimbo1
10/12/2020
06:50
You clearly know your scientific stuff. Im just a simple market participant who can tell when a price move is significant (doesn't really matter why from my perspective). In the Editas announcement they mention the manufacturing process... their partner in this is maxcyte....that to me is very significant to us as maxcyte shareholders - I would have liked Maxcyte to issue an RNS (even rns reach) rather than tweet about it. Many investors over the pond like the editas news and Im sure some investors over here would like the maxcyte link to this. But only a few people like us know about maxcyte's endeavours in this space.
nimbo1
09/12/2020
20:28
You are attributing the movement in the share price to the EDIT-301 presentation. I would argue share price movement is more likely to do with EDIT-201 (healthy donor NK cells) developments which was the subject of two presentations at ASH. See also recent performance of NKTX and FATE. I hope EDIT-301 does well but it's 2+ years behind CTX-001 and not obviously differentiated/better. Or it could be a relief rally of sorts following a flat performance YTD in a sector that's been performing very well. The good news is we'll never know. The use of MXCT technology in EDIT-301 was announced (via RNS) on 7 October 2019. "We look forward to working with MaxCyte and using its leading technology to develop EDIT-301 as a best-in-class medicine for the treatment of sickle cell disease and beta-thalassemia, and for up to four engineered cell medicines to treat cancer," said Charles Albright, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine.
gsbmba99
09/12/2020
16:31
Well the market disagree's with you - the editas share price has doubled in 5 days. My reference to breakthrough was in terms of PR for maxcyte... as in its a big breakthrough their tech is used by a serious gene editing company as a solution to manufacturing plans...that imo is rns worthy.
nimbo1
07/12/2020
20:32
I don't think the Editas announcement is a breakthrough. It's preclinical data and they haven't yet filed for an IND which would permit them to undertake clinical trials in humans. I think the most important element of the Editas announcement is their comment on manufacturing: "... the Company’s large-scale manufacturing process was shown to be consistent and robust." Earlier this year, Allogene had a slide covering the accomplishments of their ALLO-501 trial and the first bullet point was that they had "ticked the box" on the manufacturing process. There's good potential for one or more registrational Phase 2 trial initiations in 2021 which bring an early 7 figure milestone (once all of the milestones associated with the registrational trial have been earned). A registrational Phase 2 would also result in a faster time to market (since you skip Phase 3). This strategy was pursued by David Chang (Allogene CEO) when he was at Kite.
gsbmba99
07/12/2020
16:47
Thanks nimbo , you're a real sleuth!
assagai
07/12/2020
16:37
hTTps://twitter.com/editasmed/status/1335240120321122309 maxcyte congratulating their partner editas on their news from the weekend.
nimbo1
07/12/2020
14:47
Ah the trade was cancelled, must have been a case of fat fingers.
acuere
07/12/2020
13:09
Somebody just paid 480p for 1000. That’s a serious premium to the quoted 450.
acuere
07/12/2020
09:29
Despite my best efforts just couldn't stop myself buying another 4k this morning......
assagai
06/12/2020
14:03
thanks ref link tip. I really think this space is going to be massive and 2021 or perhaps now is when it is taking off...Still early days in this sector. My current exposure is Maxcyte 10% and Crispr 7%. Why I don't already own NVTA, PACB etc Im not sure.
nimbo1
06/12/2020
11:08
This CRISPR conference call also may be of interest: hTTp://ir.crisprtx.com/events/event-details/piper-sandler-32nd-annual-virtual-healthcare-conference transcript of the call here: hTTps://seekingalpha.com/article/4392593-crispr-therapeutics-ag-crsp-ceo-samarth-kulkarni-piper-sandler-32nd-annual-virtual-healthcare nimbo, you can make a link work by changing the t's in http to capitals (hTTp).
homebrewruss
06/12/2020
10:28
hTTps://www.investors.com/how-to-invest/tesla-stock-sq-stock-lead-tech-surging-higher/ anyone interested in maxcyte or genomics should listen to this presentation from august from Cathy wood for 22 mins. Then look at the share prices of the top stocks in the genomics etf. Crispr, Arcturus, Pacific biosciences, Invitae, Twist, Personalis etc. Maxcyte is the enabling platform for crispr and Editas along with others (you can see deals struck).
nimbo1
05/12/2020
23:08
I have no idea on carma as I have no insight other than rns's. I'm not concerned, this year or q1 next...what I am bothered about is maxcyte going to nasdaq asap.
nimbo1
05/12/2020
22:41
Thanks for posting that link. My largest position too. Looking forward to the next several years and just hoping that they don’t exit to something way beneath what they could achieve
adamb1978
05/12/2020
22:16
Due you still think the Carma Spinout will happen this year?
assagai
05/12/2020
21:58
I noticed I spelled your name wrong too... issue with typing on a phone... This news is very significant - this could be the first drug made using maxcyte's platform... still some way off but no wonder maxcyte confident already for next year...there will be increasingly significant milestone payments at some point. In all seriousness this is a $750mil-$1bil company on nasdaq imo all being well.
nimbo1
Chat Pages: Latest  15  14  13  12  11  10  9  8  7  6  5  4  Older
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210423 04:42:18